Long term response to interferon treatment in chronic hepatitis C patients is associated with a significant reduction in anti-E1 envelope antibody titers

Journal of Medical Virology

Volumn 60, Issue 2, 2000, Pages 126-132

  Depraetere, Stany ^a,c   Kerschaever, Els Van ^c   Vlierberghe, Hans Van ^a   Elewaut, André ^a   Brouwer, Johannes T ^b   Niesters, Hubert G M ^b   Schalm, Solko W ^b   Maertens, Geert ^c   Leroux Roels, Geert ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c INNOGENETICS   (Belgium)

Author keywords

Anti envelope antibodies; Hepatitis C virus; Humoral response; Interferon therapy; Monitoring outcome of therapy; Prediction of therapy outcome

Indexed keywords

ALPHA INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN; VIRUS RNA;

ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CHRONIC HEPATITIS; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERFERON PRODUCTION; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; TREATMENT OUTCOME; VIRUS ENVELOPE;

ANTIGENS, VIRAL; ANTIVIRAL AGENTS; GENOTYPE; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; IMMUNOENZYME TECHNIQUES; INTERFERON ALFA-2B; MONITORING, IMMUNOLOGIC; RETROSPECTIVE STUDIES; RNA, VIRAL; VIRAL ENVELOPE PROTEINS;

DNA VIRUSES; HEPATITIS C VIRUS;

EID: 0033986716     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9071(200002)60:2<126::AID-JMV4>3.0.CO;2-L     Document Type: Article

References (42)

1. Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, Hu PY, Miller MK, Gerber MA, Sampliner RE. 1989. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 327:1899-1905.
2. Ballardini G, Manzin A, Giostra F, Francesconi R, Groff P, Grassi A, Solforosi L, Ghetti S, Zauli D, Clementi M, Bianchi FB. 1997. Quantitative liver parameters of HCV infection: relation to HCV genotypes, viremia and response to interferon treatment. J Hepatol 26:779-786.
3. Barrera JM, Bruguera M, Ercilla MG, Gil C, Celis R, Gil MP, del Valle Onorato M, Rodes J, Ordinas A. 1995. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology 21:639-644.
4. Bosman F, Vandeponseele P, Rockele I, Venneman A, de Martynoff G, Maertens G. 1997. Purification of the Hepatitis C virus envelope proteins and analysis of their oligomeric state. Hepatology 26:412A.
5. Brouwer JT, Nevens F, Kleter B, Elewaut A, Adler M, Brenard R, Chamuleau RAFM, Michielsen PP, Pirotte J, Hautekeete ML, Weber J, Bourgeois N, Hansen BE, Bronkhorst CM, ten Kate FJ, Keijtink RA, Fevery J, Schalm SW. 1998. Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients. J Hepatol 28:951-959.
6. Bukh J, Miller RH, Purcell RH. 1995. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 15:41-63.
7. Chien DY, Choo QL, Ralston R, Spaete R, Tong M, Houghton M, Kuo G. 1993. Persistence of HCV despite antibodies to both putative envelope glycoproteins [letter]. Lancet 342:933.
8. Choo QL, Kuo G, Ralston R, Weiner A, Chien D, Van Nest G, Han J, Berger K, Thudium D, Kuo C, et al. 1994. Vaccination of chimpanzees against infection by the hepatitis C Virus Proc Natl Acad Sci USA 91:1294-1298.
9. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. 1989. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359-362.
10. Conjeevaram HS, Everhard JE, Hoofnagle JH. 1995. Predictors of a sustained beneficial response to interferon alfa therapy in chronic hepatitis C [editorial]. Hepatology 22:1326-1329.
11. Davis GL, Lau JY. 1997. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 26:122s-127s.
12. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, Solinas A, Mura D, Brouwer JT, Thomas H, Njapoum C, Casarin C, Bonetti P, Fuschi P, Basho J, Tocco A, Bhalla A, Galassini R, Noventa F, Schalm SW, Realdi G. 1997. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients [see comments]. Gastroenterology 112:463-472.
13. Fournillier Jacob A, Lunel F, Cahour A, Cresta P, Frangeul L, Perrin M, Girard M, Wychowski C. 1996. Antibody responses to hepatitis C envelope proteins in patients with acute or chronic hepatitis C. J Med Virol 50:159-167.
14. Frangeul L, Cresta P, Perrin M, Musset L, Opolon P, Huraux J, Lunel F. 1998. Pattern of HCV antibodies with special reference to NS5A reactivity in HCV-infected patients: relation to viral genotype, cryoglobulinemia and response to interferon. J Hepatol 28:538-543.
15. Grakoui A, Wychowski C, Lin C, Feinstone SM, Rice CM. 1993. Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol 67:1385-1395.
16. Harada S, Suzuki R, Ando A, Watanabe Y, Yagi S, Miyamura T, Saito I. 1995. Establishment of a cell line constitutively expressing E2 glycoprotein of hepatitis C virus and humoral response of hepatitis C patients to the expressed protein. J Gen Virol 76:1223-1231.
17. Hijikata M, Mizushima H, Tanji Y, Komoda Y, Hirowatari Y, Akagi T, Kato N, Kimura D, Shimotohno K. 1993. Proteolytic processing and membrane association of putative nonstructural proteins of hepatitis C virus. Proc Natl Acad Sci USA 90:10773-10777.
18. Hirayama M, Maruyama T, Koike K, Mitsui H, Maekawa H, Yamada H, Yotsuyanagi H, Lino S, Yasuda K, Milich D. 1997. The changes in antibody levels against synthetic HCV core peptides are useful for predicting the long-term outcome after interferon treatment. Hepatology 26:211A.
19. Hoofnagle JH, di Bisceglie AM. 1997. The treatment of chronic viral hepatitis. N Engl J Med 336:347-356.
20. Hussy P, Faust H, Wagner JC, Schmid G, Mous J, Jacobsen H. 1997. Evaluation of hepatitis C virus envelope proteins expressed in E. coli and insect cells for use as tools for antibody screening. J Hepatol 26:1179-1186.
21. Inudoh M, Nyunoya H, Tanaka T, Hijikata M, Kato N, Shimotohno K. 1996. Antigenicity of hepatitis C virus envelope proteins expressed in Chinese hamster ovary cells. Vaccine 14:1590-1596.
22. Kohara M, Tsukiyama-Kohara K, Maki N, Asano K, Yamaguchi K, Miki K, Tanaka S, Hattori N, Matsuura Y, Saito I, Miyamura T, Nomoto A. 1992. Expression and characterization of glycoprotein gp35 of hepatitis C virus using recombinant vaccinia virus. J Gen Virol 73:2313-2318.
23. Lee DS, Lesniewski RR, Sung YC, Min WK, Park SG, Lee KH, Kim HS. 1996. Significance of anti-E2 in the diagnosis of HCV infection in patients on maintenance hemodialysis: anti-E2 is frequently detected among anti-HCV antibody-negative patients. J Am Soc Nephrol 7:2409-2413.
24. Lee KJ, Suh YA, Cho YG, Cho YS, Ha GW, Chung KH, Hwang JH, Yun YD, Lee DS, Kim CM, Sung YC. 1997. Hepatitis C virus E2 protein purified from mammalian cells is frequently recognized by E2-specific antibodies in patient sera. J Biol Chem 272:30040-30046.
25. Lesniewski R, Okasinski G, Carrick R, Van Sant C, Desai S, Johnson R, Scheffel J, Moore B, Mushahwar I. 1995. Antibody to hepatitis C virus second envelope (HCV-E2) glycoprotein: a new marker of HCV infection closely associated with viremia. J Med Virol 45:415-422.
26. Lindsay KL. 1997. Therapy of hepatitis C: overview. Hepatology 26:71s-77s.
27. Lindsay KL, Davis GL, Schiff ER, Bodenheimer HC, Balart LA, Dienstag JL, Perrillo RP, Tamburro CH, GoffHS, Everson GT, Silva M, Katkov WN, Goodman Z, Lau JY, Maertens G, Gogate J, Sanghvi B, Albrecht J. 1996. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatitis Interventional Therapy Group. Hepatology 24:1034-1040.
28. Maertens G, Stuyver L. 1997. Genotypes and genetic variation of hepatitis C virus. In: T.J. Harrison and A.J. Zuckerman, editors. New York: John Wiley & Sons, Inc. 183-233.
29. Martinot Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, Degott C, Descombes I, Le Breton V, Milotova V. 1995. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 22:1050-1056.
30. Mink MA, Benichou S, Madaule P, Tiollais P, Prince AM, Inchauspe G. 1994. Characterization and mapping of a B-cell immunogenic domain in hepatitis C virus E2 glycoprotein using a yeast peptide library. Virology 200:246-255.
31. Psichogiou M, Katsoulidou A, Vaindirli E, Francis B, Lee SR, Hatzakis A. 1997. Immunologic events during the incubation period of hepatitis C virus infection: the role of antibodies to E2 glycoprotein. Multicentre Hemodialysis Cohort Study and Viral Hepatitis. Transfusion 37:858-862.
32. Reichard O, Schvarcz R, Weiland O. 1997. Therapy of hepatitis C: alpha interferon and ribavirin. Hepatology 26:108s-111s.
33. Saracco G, Abate ML, Baldi M, Calvo PL, Manzini P, Brunetto MR, Oliven F, Kuo G, Chien D, Houghton M, et al. 1994. Hepatitis C virus markers in patients with longterm biochemical and histological remission of chronic hepatitis. Liver 14:65-70.
34. Serfaty L, Giral P, Loria A, Andreani T, Legendre C, Poupon R. 1994. Factors predictive of the response to interferon in patients with chronic hepatitis C [see comments]. J Hepatol 21:12-17.
35. Shindo M, Arai K, Okuno T. 1997. The clinical value of grading and staging scores for predicting a long-term response and evaluating the efficacy of interferon therapy in chronic hepatitis C. J Hepatol 26:492-497.
36. Shiratori Y, Kato N, Yokosuka O, Imazeki F, Hashimoto E, Hayashi N, Nakamura A, Asada M, Kuroda H, Tanaka N, Arakawa Y, Omata M. 1997. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group. Gastroenterology 113:558-566.
37. Stuyver L, Van Arnhem W, Wyseur A, DeLeys R, Maertens G. 1993. Analysis of the putative E1 envelope and NS4a epitope regions of HCV type 3. Biochem Biophys Res Commun 192:635-641.
38. Stuyver L, van Arnhem W, Wyseur A, Maertens G. 1994. Cloning and phylogenetic analysis of the core, E2, and NS3/NS4 regions of the hepatitis C virus type 5a. Biochem Biophys Res Commun 202:1308-1314.
39. Yan BS, Liao LY, Leou K, Chang YC, Syu WJ. 1994. Truncating the putative membrane association region circumvents the difficulty of expressing hepatitis C virus protein E1 in Escherichia coli. J Virol Methods 49:343-351.
40. Yokosuka O, Omata M, Ito Y, Ohto M. 1993. Expression of HCV E2/ NS1 protein as a fusion protein with maltose binding protein: detection of anti-E2/NS1 antibody in chronic liver disease. Gut 34:S64-S65.
41. Yuki N, Hayashi N, Kasahara A, Hagiwara H, Mita E, Ohkawa K, Katayama K, Fusamoto H, Kamada T. 1996. Quantitative analysis of antibody to hepatitis C virus envelope 2 glycoprotein in patients with chronic hepatitis C virus infectioin. Hepatology 23:947-952.
42. Zaaijer HL, Vallari DS, Cunningham M, Lesniewski R, Reesink HW, van der Poel CL, Lelie PN. 1994. E2 and NS5: new antigens for detection of hepatitis C virus antibodies. J Med Virol 44:395-397.